Gastrointestinal Stromal Tumor Market Report 2026

The gastrointestinal stromal tumor market size has grown strongly in recent years. It will grow from $1.36 billion in 2025 to $1.46 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to approval of imatinib therapy, improved tumor classification, expansion of oncology care centers, increased awareness of rare gi tumors, availability of surgical interventions.

The gastrointestinal stromal tumor market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to development of next-generation targeted therapies, growth in precision diagnostics, increased clinical trials, expansion of personalized cancer treatment, improved survival outcomes. Major trends in the forecast period include rising use of targeted tyrosine kinase inhibitors, increased focus on molecular tumor profiling, expansion of precision oncology approaches, growth in surgical and drug combination therapy, improved long-term disease management.

The rising incidence of stomach cancer is expected to drive the growth of the gastrointestinal stromal tumor (GIST) market in the coming years. Stomach cancer is characterized by the uncontrolled growth and multiplication of malignant cells in the stomach lining. While GISTs can occur in the stomach, they are distinct from stomach cancer. Patients with GISTs who develop two separate tumors merging into one have been found to have an increased risk of additional cancers, including small bowel adenocarcinoma. For example, in January 2024, the American Cancer Society, a US-based professional organization, projected approximately 26,890 new stomach cancer cases and 10,880 deaths in the United States in 2024, accounting for 1.5% of all new cancer diagnoses. Therefore, the growing incidence of stomach cancer is driving the gastrointestinal stromal tumor market.

Key players in the gastrointestinal stromal tumor market are developing new drugs, including signal transduction and targeted therapies, to improve treatment efficacy, overcome resistance to existing therapies, and address unmet clinical needs. Signal transduction and targeted therapies are designed to block or modify specific cellular signaling pathways that promote tumor growth and survival. For instance, in November 2025, Ascentage Pharma Group International Inc., a China-based commercial-stage biopharmaceutical company, published Phase Ib clinical data for olverembatinib (HQP1351) in Signal Transduction and Targeted Therapy, demonstrating promising efficacy and safety in SDH-deficient GISTs and revealing a new antitumor mechanism involving lipid metabolism modulation.

In February 2025, GSK plc, a U.K.-based global biopharmaceutical company specializing in prescription medicines, vaccines, and specialty treatments, acquired IDRx, Inc. for an undisclosed amount. Through this acquisition, GSK aims to strengthen its precision oncology portfolio and expand its pipeline of targeted therapies for GISTs. IDRx, Inc., a U.S.-based clinical-stage biotechnology company, develops precision therapies for rare cancers, focusing on molecularly driven GIST treatments, including its lead KIT tyrosine kinase inhibitor, IDRX 42.

Major companies operating in the gastrointestinal stromal tumor market are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd.

North America was the largest region in the gastrointestinal stromal tumor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastrointestinal stromal tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gastrointestinal stromal tumor market by increasing costs of imported oncology drugs, diagnostic testing tools, and specialty medicines. Cancer treatment centers and hospitals are most affected due to reliance on imported targeted therapies. These tariffs raise treatment costs by increasing expenses for long-term targeted drug therapy and molecular diagnostics. However, they encourage domestic oncology drug development, supporting localized production of specialty cancer treatments.

The gastrointestinal stromal tumor market research report is one of a series of new reports that provides gastrointestinal stromal tumor market statistics, including gastrointestinal stromal tumor industry global market size, regional shares, competitors with a gastrointestinal stromal tumor market share, detailed gastrointestinal stromal tumor market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal stromal tumor industry. This gastrointestinal stromal tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A gastrointestinal stromal tumor (GIST) is a rare, non-epithelial tumor that develops in the gastrointestinal (GI) tract. These tumors most commonly arise in the stomach or small intestine, but they can occur anywhere along the GI tract, from the esophagus to the rectum.

The primary treatment options for gastrointestinal stromal tumors include chemotherapy, targeted therapy, and others. Chemotherapy is a medical approach that employs potent drugs to target and destroy rapidly dividing cells in the body, including cancer cells. It is used for various indications, such as tumors in the stomach and small intestine, and is administered by different end-users, including hospitals, clinics, specialized cancer treatment centers, and others.

The gastrointestinal stromal tumor market includes revenues earned by entities by providing services such as diagnostic services, pathology services, pathology services, and pathology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal stromal tumor market also includes sales of targeted therapy, chemotherapy, radiation therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.